Literature DB >> 7927854

Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients.

P Maire1, X Barbaut, P Girard, A Mallet, R W Jelliffe, T Berod.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7927854     DOI： 10.1016/0020-7101(94)90106-6

Source DB:  PubMed          Journal:  Int J Biomed Comput        ISSN： 0020-7101


× No keyword cloud information.
  5 in total

1.  A Bayesian approach to tracking patients having changing pharmacokinetic parameters.

Authors:  David S Bayard; Roger W Jelliffe
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

2.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Renal elimination of amikacin and the aging process.

Authors:  M Ducher; P Maire; C Cerutti; Y Bourhis; F Foltz; P Sorensen; R Jelliffe; J P Fauvel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

5.  Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.

Authors:  Christoffer W Tornøe; Henrik Agersø; Henrik A Nielsen; Henrik Madsen; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-12       Impact factor: 2.745
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.